ARWR Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.50%

Insider Buying (Last 12 Months): $54,990.00

Insider Selling (Last 12 Months): $10,412,959.13

Arrowhead Pharmaceuticals Insider Trading History Chart

Arrowhead Pharmaceuticals Share Price & Price History

^$20.61

▼ -0.88 (-4.09%)

As of 09/16/2024 04:25 PM ET

Days: 30 | 90 | 365

It’s over.

From Behind the Markets | Ad

We found a tiny company which provides the backbone for the entire $15.7 trillion AI industry... It's used by EVERY single AI company on the planet... AMD, NVIDIA, META... none of these companies could exist without this firm.

Click here for the ticker >>>

Arrowhead Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/2/2024	Tracie Oliver	Insider	Sell	9,394	$25.28	$237,480.32	127,107
5/2/2024	Victoria Vakiener	Director	Sell	1,799	$23.31	$41,934.69	30,205
3/20/2024	Hongbo Lu	Director	Buy	1,000	$27.50	$27,500.00	33,680
3/18/2024	Hongbo Lu	Director	Buy	1,000	$27.49	$27,490.00	31,680
3/6/2024	Kenneth Allen Myszkowski	CFO	Sell	40,000	$35.19	$1,407,600.00	400,600
1/31/2024	Christopher Richard Anzalone	CEO	Sell	57,499	$32.35	$1,860,092.65	3,715,048
1/12/2024	James C. Hamilton	Insider	Sell	7,940	$36.89	$292,906.60	210,851
1/11/2024	Douglas B Given	Director	Sell	2,911	$38.06	$110,792.66	129,711
1/5/2024	James C. Hamilton	Insider	Sell	32,143	$35.18	$1,130,790.74	218,791
1/5/2024	Kenneth Allen Myszkowski	CFO	Sell	16,104	$35.27	$567,988.08	440,600
1/5/2024	Patrick C. O'Brien	COO	Sell	22,841	$35.27	$805,602.07	464,385
1/3/2024	James C. Hamilton	Insider	Sell	6,300	$32.19	$202,797.00	175,934
1/3/2024	Patrick C. O'Brien	COO	Sell	8,749	$32.28	$282,417.72	403,826
1/2/2024	Christopher Richard Anzalone	CEO	Sell	9,952	$31.01	$308,611.52	3,715,048
12/20/2023	Christopher Richard Anzalone	CEO	Sell	12,000	$28.54	$342,480.00	3,725,000
11/20/2023	Javier San Martin	Insider	Sell	19,700	$28.80	$567,360.00	131,800
10/25/2023	Christopher Richard Anzalone	CEO	Sell	24,338	$24.21	$589,222.98	3,737,000
9/28/2023	Victoria Vakiener	Director	Sell	1,550	$26.33	$40,811.50	21,734
9/18/2023	Christopher Richard Anzalone	CEO	Sell	57,755	$28.12	$1,624,070.60	3,761,338
7/3/2023	Tracie Oliver	Insider	Sell	8,925	$35.31	$315,141.75	61,575
6/30/2023	James C. Hamilton	Insider	Sell	3,000	$35.53	$106,590.00	188,484
6/27/2023	Kenneth Allen Myszkowski	CFO	Sell	15,000	$36.20	$543,000.00	381,704
5/5/2023	Douglas B Given	Director	Sell	6,500	$40.90	$265,850.00	117,635
5/3/2023	Christopher Richard Anzalone	CEO	Sell	54,928	$39.14	$2,149,881.92	3,761,338
3/3/2023	Adeoye Y. Olukotun	Director	Sell	11,350	$32.65	$370,577.50	7,867
2/27/2023	Douglas B Given	Director	Sell	875	$32.62	$28,542.50	13,000
1/9/2023	William D. Waddill	Director	Sell	3,200	$30.00	$96,000.00	28,950
1/5/2023	James C. Hamilton	Insider	Sell	13,803	$37.40	$516,232.20	191,484
1/5/2023	Patrick C. O'Brien	COO	Sell	15,000	$37.39	$560,850.00	413,375
1/3/2023	James C. Hamilton	Insider	Sell	10,338	$38.38	$396,772.44	145,287
1/3/2023	Patrick C. O'Brien	COO	Sell	17,500	$38.33	$670,775.00	363,375
12/29/2022	Kenneth Allen Myszkowski	CFO	Sell	30,625	$40.00	$1,225,000.00	336,704
11/21/2022	Javier San Martin	Insider	Sell	19,500	$29.99	$584,805.00	91,500
2/11/2022	Christopher Richard Anzalone	CEO	Sell	146,388	$51.91	$7,599,001.08
1/5/2022	Kenneth Allen Myszkowski	CFO	Sell	40,000	$61.70	$2,468,000.00
1/5/2022	Patrick C. O'Brien	General Counsel	Sell	32,500	$61.72	$2,005,900.00
1/4/2022	James C. Hamilton	SVP	Sell	19,375	$65.49	$1,268,868.75
1/3/2022	William D. Waddill	Director	Sell	4,500	$64.72	$291,240.00
12/28/2021	Douglas B Given	Director	Buy	655	$66.37	$43,472.35
12/15/2021	Christopher Richard Anzalone	CEO	Sell	60,000	$67.56	$4,053,600.00
11/19/2021	Javier San Martin	Insider	Sell	19,500	$69.31	$1,351,545.00
10/22/2021	Christopher Richard Anzalone	CEO	Sell	50,000	$65.63	$3,281,500.00
10/20/2021	Christopher Richard Anzalone	CEO	Sell	15,000	$66.23	$993,450.00

My big AI project…

From Brownstone Research | Ad

On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.

Just click here to register.

SEC Filings (Institutional Ownership Changes) for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

62.61% of Arrowhead Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Arrowhead Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/16/2024	Quarry LP	8,500	$0.22M	0.1%	+54.5%	0.007%
8/16/2024	Creative Planning	28,276	$0.74M	0.0%	+9.4%	0.023%
8/16/2024	Algert Global LLC	40,466	$1.05M	0.0%	+104.3%	0.033%
8/15/2024	Scientech Research LLC	7,842	$0.20M	0.0%	-48.5%	0.006%
8/15/2024	The Manufacturers Life Insurance Company	149,156	$3.88M	0.0%	+1.1%	0.120%
8/15/2024	Millennium Management LLC	529,251	$13.76M	0.0%	+61.9%	0.426%
8/15/2024	Deerfield Management Company L.P. Series C	19,461	$0.51M	0.0%	N/A	0.016%
8/15/2024	Affinity Asset Advisors LLC	50,000	$1.30M	0.1%	-58.3%	0.040%
8/14/2024	Squarepoint Ops LLC	383,826	$9.98M	0.0%	N/A	0.309%
8/14/2024	Xponance Inc.	16,465	$0.43M	0.0%	-4.8%	0.013%
8/14/2024	Bank of Montreal Can	43,699	$1.20M	0.0%	+240.5%	0.035%
8/14/2024	Avoro Capital Advisors LLC	8,888,888	$231.02M	3.1%	+3.9%	7.157%
8/14/2024	ProShare Advisors LLC	29,081	$0.76M	0.0%	-18.3%	0.023%
8/14/2024	Profund Advisors LLC	32,003	$0.83M	0.0%	-34.6%	0.026%
8/13/2024	Thrivent Financial for Lutherans	30,009	$0.78M	0.0%	-3.3%	0.024%
8/13/2024	Sei Investments Co.	9,908	$0.26M	0.0%	-8.0%	0.008%
8/13/2024	Pacer Advisors Inc.	19,474	$0.51M	0.0%	-2.4%	0.016%
8/12/2024	Seven Eight Capital LP	34,561	$0.90M	0.1%	-54.1%	0.028%
8/12/2024	Vanguard Personalized Indexing Management LLC	12,751	$0.33M	0.0%	+23.2%	0.010%
8/12/2024	Amalgamated Bank	60,052	$1.56M	0.0%	-7.1%	0.048%
8/12/2024	E Fund Management Co. Ltd.	8,900	$0.23M	0.0%	-31.3%	0.007%
8/10/2024	Mutual of America Capital Management LLC	71,111	$1.85M	0.0%	-3.7%	0.057%
8/9/2024	Edgestream Partners L.P.	53,918	$1.40M	0.1%	N/A	0.043%
8/9/2024	Dimensional Fund Advisors LP	145,874	$3.79M	0.0%	+139.1%	0.117%
8/8/2024	Federated Hermes Inc.	7,201	$0.19M	0.0%	-51.1%	0.006%
8/8/2024	DekaBank Deutsche Girozentrale	36,235	$0.93M	0.0%	-4.3%	0.029%
8/8/2024	Meeder Asset Management Inc.	3,405	$88K	0.0%	+4,629.2%	0.003%
8/8/2024	State of New Jersey Common Pension Fund D	81,323	$2.11M	0.0%	-11.1%	0.065%
8/7/2024	Texas Permanent School Fund Corp	100,304	$2.61M	0.0%	-7.5%	0.081%
8/5/2024	Arizona State Retirement System	34,685	$0.90M	0.0%	+2.4%	0.028%
8/5/2024	Victory Capital Management Inc.	41,090	$1.07M	0.0%	+67.3%	0.033%
8/3/2024	TD Asset Management Inc	54,200	$1.41M	0.0%	+90.8%	0.044%
8/2/2024	Wealth Effects LLC	159,600	$4.15M	1.5%	-3.0%	0.129%
8/1/2024	Rhumbline Advisers	383,029	$9.96M	0.0%	+2.9%	0.308%
8/1/2024	Privium Fund Management B.V.	286,936	$7.24M	1.9%	+4.7%	0.231%
7/31/2024	nVerses Capital LLC	3,700	$96K	0.1%	N/A	0.003%
7/31/2024	Commonwealth Equity Services LLC	34,663	$0.90M	0.0%	+3.7%	0.028%
7/29/2024	Crossmark Global Holdings Inc.	7,828	$0.20M	0.0%	-6.3%	0.006%
7/29/2024	Principal Financial Group Inc.	424,766	$11.04M	0.0%	-12.3%	0.342%
7/29/2024	Zurcher Kantonalbank Zurich Cantonalbank	28,739	$0.75M	0.0%	+20.7%	0.023%
7/26/2024	State of Michigan Retirement System	29,870	$0.78M	0.0%	-2.0%	0.024%
7/26/2024	Bank of New York Mellon Corp	1,085,069	$28.20M	0.0%	+2.9%	0.874%
7/26/2024	EFG Asset Management North America Corp.	51,828	$1.35M	0.2%	+86.8%	0.042%
7/25/2024	Banque Pictet & Cie SA	104,792	$2.72M	0.0%	-3.0%	0.084%
7/24/2024	Retirement Systems of Alabama	153,292	$3.98M	0.0%	-56.0%	0.123%
7/24/2024	Louisiana State Employees Retirement System	35,100	$0.91M	0.0%	-1.7%	0.028%
7/22/2024	Fifth Third Bancorp	1,186	$31K	0.0%	+42.5%	0.001%
7/20/2024	China Universal Asset Management Co. Ltd.	14,592	$0.38M	0.1%	-38.8%	0.012%
7/20/2024	Hennion & Walsh Asset Management Inc.	24,880	$0.65M	0.0%	-45.6%	0.020%
7/18/2024	Assenagon Asset Management S.A.	88,150	$2.29M	0.0%	-74.4%	0.071%
7/17/2024	Oak Ridge Investments LLC	36,600	$0.95M	0.1%	-12.7%	0.029%
7/12/2024	SG Americas Securities LLC	9,369	$0.24M	0.0%	+27.4%	0.008%
7/10/2024	CWM LLC	80,169	$2.08M	0.0%	-19.3%	0.065%
5/20/2024	Virtu Financial LLC	9,411	$0.27M	0.0%	N/A	0.008%
5/17/2024	Comerica Bank	48,312	$1.38M	0.0%	+11.2%	0.039%
5/16/2024	California State Teachers Retirement System	122,486	$3.50M	0.0%	+14.1%	0.099%
5/16/2024	Janus Henderson Group PLC	57,449	$1.64M	0.0%	+21.3%	0.046%
5/16/2024	Bayesian Capital Management LP	25,303	$0.72M	0.1%	N/A	0.020%
5/16/2024	Silvercrest Asset Management Group LLC	150,198	$4.30M	0.0%	+49.9%	0.121%
5/15/2024	Price T Rowe Associates Inc. MD	71,136	$2.04M	0.0%	+17.4%	0.057%
5/15/2024	Avoro Capital Advisors LLC	8,555,555	$244.69M	2.9%	+657.1%	6.889%
5/15/2024	Affinity Asset Advisors LLC	120,000	$3.43M	0.4%	N/A	0.097%
5/14/2024	Capital International Investors	479,106	$13.70M	0.0%	-62.5%	0.386%
5/14/2024	Natixis	204,000	$5.83M	0.0%	N/A	0.164%
5/14/2024	CANADA LIFE ASSURANCE Co	90,571	$2.59M	0.0%	+9.8%	0.073%
5/14/2024	American International Group Inc.	220,217	$6.30M	0.0%	+13.4%	0.177%
5/13/2024	Evolutionary Tree Capital Management LLC	44,896	$1.28M	1.3%	-13.1%	0.036%
5/13/2024	Seven Eight Capital LP	75,224	$2.15M	0.2%	+592.3%	0.061%
5/13/2024	Ameritas Investment Partners Inc.	38,867	$1.11M	0.0%	+13.6%	0.031%
5/10/2024	Ontario Teachers Pension Plan Board	87,883	$2.51M	0.0%	+1,239.3%	0.071%
5/10/2024	Vanguard Group Inc.	12,404,050	$354.76M	0.0%	+16.2%	10.012%
5/10/2024	Gratus Wealth Advisors LLC	12,250	$0.35M	0.1%	N/A	0.010%
5/9/2024	State Board of Administration of Florida Retirement System	33,353	$0.95M	0.0%	+14.2%	0.027%
5/8/2024	ProShare Advisors LLC	35,592	$1.02M	0.0%	+21.7%	0.029%
5/8/2024	US Bancorp DE	43,796	$1.25M	0.0%	-5.2%	0.035%
5/8/2024	Russell Investments Group Ltd.	242,636	$6.94M	0.0%	-2.1%	0.196%
5/8/2024	Headlands Technologies LLC	2,417	$69K	0.0%	+7,696.8%	0.002%
5/7/2024	Susquehanna Fundamental Investments LLC	128,083	$3.66M	0.2%	N/A	0.103%
5/7/2024	Swiss National Bank	243,300	$6.96M	0.0%	+21.2%	0.196%
5/7/2024	Nvwm LLC	27,581	$0.79M	0.2%	N/A	0.022%
5/7/2024	SG Americas Securities LLC	7,355	$0.21M	0.0%	-78.8%	0.006%
5/6/2024	Texas Permanent School Fund Corp	108,433	$3.10M	0.0%	+17.3%	0.088%
5/3/2024	Essex Investment Management Co. LLC	72,299	$2.07M	0.4%	N/A	0.058%
5/2/2024	Mutual of America Capital Management LLC	73,826	$2.11M	0.0%	+11.5%	0.060%
5/2/2024	Nordea Investment Management AB	153,357	$4.45M	0.0%	-1.8%	0.124%
5/1/2024	BNP Paribas Financial Markets	116,091	$3.32M	0.0%	-52.3%	0.094%
5/1/2024	Oak Ridge Investments LLC	41,932	$1.20M	0.1%	-3.9%	0.034%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	327,782	$9.38M	0.0%	+67.2%	0.265%
4/30/2024	Retirement Systems of Alabama	348,784	$9.98M	0.0%	+6.5%	0.282%
4/30/2024	Commonwealth Equity Services LLC	33,413	$0.96M	0.0%	-1.5%	0.027%
4/29/2024	Principal Financial Group Inc.	484,120	$13.85M	0.0%	+17.5%	0.391%
4/29/2024	China Universal Asset Management Co. Ltd.	23,838	$0.68M	0.1%	+91.8%	0.019%
4/26/2024	Securian Asset Management Inc.	10,100	$0.29M	0.0%	+12.5%	0.008%
4/26/2024	Yousif Capital Management LLC	57,393	$1.64M	0.0%	+9.9%	0.046%
4/25/2024	New York State Teachers Retirement System	138,683	$3.97M	0.0%	+2.1%	0.112%
4/25/2024	WCM Investment Management LLC	225,583	$6.45M	0.0%	+30.5%	0.182%
4/24/2024	Assenagon Asset Management S.A.	344,467	$9.85M	0.0%	+796.9%	0.278%
4/23/2024	Louisiana State Employees Retirement System	35,700	$1.02M	0.0%	+18.6%	0.029%
4/23/2024	Amalgamated Bank	64,664	$1.85M	0.0%	-3.0%	0.052%
4/23/2024	Wealth Effects LLC	164,460	$4.70M	1.7%	+1.6%	0.133%

Data available starting January 2016

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $20.61

$20.59

$21.51

50 Day Range

MA: $25.25

$20.24

$29.54

52 Week Range

Now: $20.61

$20.14

$39.83

Volume

402,612 shs

Average Volume

1,222,339 shs

Market Capitalization

$2.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96

Who are the company insiders with the largest holdings of Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals' top insider shareholders include:
Christopher Richard Anzalone (CEO)
Patrick O'brien (COO)
Kenneth Allen Myszkowski (CFO)
James C Hamilton (Insider)
Martin Javier San (Insider)
Douglas B Given (Director)
Tracie Oliver (Insider)
Hongbo Lu (Director)
Victoria Vakiener (Director)
William D Waddill (Director)
Adeoye Y Olukotun (Director)
Learn More about top insider investors at Arrowhead Pharmaceuticals.
Who are the major institutional investors of Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals' top institutional shareholders include:
Avoro Capital Advisors LLC — 7.16%
Bank of New York Mellon Corp — 0.87%
Millennium Management LLC — 0.43%
Principal Financial Group Inc. — 0.34%
Squarepoint Ops LLC — 0.31%
Rhumbline Advisers — 0.31%
Learn More about top institutional investors of Arrowhead Pharmaceuticals stock.
Which institutional investors are selling Arrowhead Pharmaceuticals stock?: During the last quarter, ARWR stock was sold by these institutional investors:
Assenagon Asset Management S.A.
Retirement Systems of Alabama
Affinity Asset Advisors LLC
Principal Financial Group Inc.
Seven Eight Capital LP
Hennion & Walsh Asset Management Inc.
CWM LLC
Profund Advisors LLC
In the last year, company insiders that have sold Arrowhead Pharmaceuticals company stock include:
Christopher Richard Anzalone (CEO)
Patrick O'brien (COO)
Kenneth Allen Myszkowski (CFO)
James C Hamilton (Insider)
Martin Javier San (Insider)
Douglas B Given (Director)
Tracie Oliver (Insider)
Hongbo Lu (Director)
Learn More investors selling Arrowhead Pharmaceuticals stock.
Which institutional investors are buying Arrowhead Pharmaceuticals stock?: Within the last quarter, ARWR stock was acquired by institutional investors including:
Squarepoint Ops LLC
Avoro Capital Advisors LLC
Millennium Management LLC
Dimensional Fund Advisors LP
Edgestream Partners L.P.
Bank of Montreal Can
Bank of New York Mellon Corp
TD Asset Management Inc